News
ALZN
1.020
-1.92%
-0.020
Weekly Report: what happened at ALZN last week (0406-0410)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL)
TipRanks · 04/07 17:20
Alzamend Neuro’s AL001 shows “encouraging” data in Phase II brain trial
TipRanks · 04/07 12:16
Alzamend Neuro Announces Pharmacodynamic Findings From Brain Magnetic Resonance Spectroscopy Analysis Conducted In Healthy Human Subjects In Trial Conducted At Massachusetts General Hospital
Benzinga · 04/07 12:15
Alzamend reports encouraging Phase II brain MRS data for AL001 lithium therapy
Reuters · 04/07 12:01
ALZAMEND NEURO REPORTS ENCOURAGING PHARMACODYNAMIC DATA FROM PHASE II CLINICAL TRIAL OF AL001 "LITHIUM IN BRAIN" STUDY IN A TRIAL CONDUCTED AT MASSACHUSETTS GENERAL HOSPITAL
Reuters · 04/07 12:00
Weekly Report: what happened at ALZN last week (0330-0403)?
Weekly Report · 04/06 10:01
Weekly Report: what happened at ALZN last week (0323-0327)?
Weekly Report · 03/30 10:02
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 03/27 17:05
Alzamend Announces Topline Data From First Phase II "Lithium In Brain" Clinical Trial, Demonstrating AL001 Meets Bioequivalence Standards, And Showing Numerically Superior Lithium Delivery To Brain Compared To Standard Lithium Carbonate
Benzinga · 03/26 12:08
Alzamend Neuro reports ‘positive’ data from Phase II clinical trial of AL001
TipRanks · 03/26 12:07
Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate
Reuters · 03/26 12:01
ALZAMEND NEURO INC - ADDITIONAL PHASE II STUDIES IN MDD, PTSD, ALZHEIMER'S EXPECTED TO BEGIN IN LATTER HALF OF 2026
Reuters · 03/26 12:00
Weekly Report: what happened at ALZN last week (0316-0320)?
Weekly Report · 03/23 09:58
Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency
TipRanks · 03/20 21:10
Alzamend Neuro faces Nasdaq delisting risk as stockholders’ equity falls to 2.2 million USD
Reuters · 03/20 20:31
Alzamend Neuro initiates Phase II trial of AL001 study
TipRanks · 03/16 12:15
Alzamend Neuro Starts Phase II Clinical Study Of AL001 In Participants With Bipolar Disorder Type 1; Topline Data Anticipated By March End
Benzinga · 03/16 12:12
Alzamend Neuro launches Phase II AL001 trial in bipolar disorder type 1 patients at Massachusetts General Hospital
Reuters · 03/16 12:01
ALZAMEND NEURO INITIATES PHASE II CLINICAL TRIAL OF AL001 "LITHIUM IN BRAIN" STUDY IN PATIENTS WITH BIPOLAR DISORDER IN COLLABORATION WITH MASSACHUSETTS GENERAL HOSPITAL
Reuters · 03/16 12:00
More
Webull provides a variety of real-time ALZN stock news. You can receive the latest news about Alzamend Neuro Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.